GT Biopharma (NASDAQ:GTBP – Get Free Report) announced its earnings results on Monday. The company reported ($1.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.50) by $0.52, reports.
GT Biopharma Stock Up 6.6%
Shares of GTBP stock traded up $0.21 during trading hours on Wednesday, hitting $3.39. 24,139 shares of the company were exchanged, compared to its average volume of 55,255. The firm has a fifty day moving average of $6.10 and a 200 day moving average of $9.01. GT Biopharma has a 1 year low of $3.10 and a 1 year high of $23.60. The firm has a market cap of $6.99 million, a PE ratio of -0.02 and a beta of 0.88.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on GTBP. Wall Street Zen lowered GT Biopharma to a “strong sell” rating in a research note on Saturday, September 12th. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, October 2nd. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, GT Biopharma presently has a consensus rating of “Sell”.
About GT Biopharma
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research centers on its TriKE platform, which is designed to direct natural killer (NK) cells toward cancer cells and support their activity using an immune-stimulating signal. The company’s pipeline includes GTB-3650, a candidate designed to target CD33-expressing blood cancers such as acute myeloid leukemia, and GTB-5550, a candidate targeting B7-H3, a protein found on various solid tumors.
See Also
- Five stocks we like better than GT Biopharma
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
